Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by
antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by …

B cells have a prominent role in the pathogenesis of systemic lupus erythematosus (SLE).
They are mediators of inflammation through the production of pathogenic antibodies that …

Celastrol, a bioactive molecule extracted from the Tripterygium wilfordii plant, has been
shown to exhibit anti-inflammatory properties. However, its mechanism of action has not …

The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for
the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares …

Autoimmune diseases strain healthcare systems worldwide as their incidence rises, and
current treatments put patients at risk for infections. An increased understanding of …

Severe acute respiratory syndrome coronavirus 2 mRNA vaccination has reduced
effectiveness in certain immunocompromised individuals. However, the cellular mechanisms …

FcγRIIB is an inhibitory receptor expressed throughout B cell development. Diminished
expression or function is associated with lupus in mice and humans, in particular through an …

Defective FAS (CD95/Apo-1/TNFRSF6) signaling causes autoimmune lymphoproliferative
syndrome (ALPS). Hypergammaglobulinemia is a common feature in ALPS with FAS …

Background B-cell depletion with rituximab (RTX) is an effective treatment for anti-neutrophil
cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients. Nevertheless, relapses …

Group 3 innate lymphoid cells (ILC3s) represent a new population in immune regulation, yet
their role in lupus nephritis (LN) remains elusive. In the present work, systemic increases in …